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Abstract
We tested the hypothesis that activation of inwardly rectifying potassium (KIR) channels and Na+K+
ATPase, two pathways that lead to hyperpolarization of vascular cells, contributes to both the onset and
steadystate hyperemic response to exercise. We also determined whether after inhibiting these pathways
nitric oxide (NO) and prostaglandins (PGs) are involved in the hyperemic response. Forearm blood flow
(FBF; Doppler ultrasound) was determined during rhythmic handgrip exercise at 10% maximal voluntary
contraction for 5 min in the following conditions: control [saline; trial 1 (T1)]; with combined inhibition of
KIR channels and Na+K+ATPase alone [via barium chloride (BaCl2) and ouabain, respectively; trial 2
(T2)]; and with additional combined nitric oxide synthase (NGmonomethylL arginine) and cyclooxygenase
inhibition [ketorolac; trial 3 (T3)]. In T2, the total hyperemic responses were attenuated ∼50% from control
(P < 0.05) at exercise onset, and there was minimal further effect in T3 (protocol 1; n = 11). In protocol 2 (n
= 8), steadystate FBF was significantly reduced during T2 vs. T1 (133 ± 15 vs. 167 ± 17 ml/min; Δ from
control: −20 ± 3%; P < 0.05) and further reduced during T3 (120 ± 15 ml/min; −29 ± 3%; P < 0.05 vs. T2).
In protocol 3 (n = 8), BaCl2 alone reduced FBF during onset (∼50%) and steadystate exercise (∼30%) as
observed in protocols 1 and 2, respectively, and addition of ouabain had no further impact. Our data
implicate activation of KIR channels as a novel contributing pathway to exercise hyperemia in humans.
Keywords: blood flow, contraction, skeletal muscle, vasodilation
and oxygen delivery to contracting skeletal muscle is a complex response
involving mechanical factors, the sympathetic nervous system, and local metabolic and endotheliumderived
substances that influence vascular tone (47). In this context, prior studies in animal models established
disruption of the endothelium attenuates the hyperemic response to muscle contraction (2, 44, 54) and
subsequent studies have attempted to identify the endothelialderived substances that may regulate blood
flow during exercise. Local metabolic substances independent of the endothelium, such as K+, have also
been suggested to be involved in exercise hyperemia (23, 29, 63), particularly at the onset of muscle
contractions (1, 7, 40). However, to date, obligatory local vasodilators for the hyperemia at exercise onset
and during steadystate conditions are still questioned in humans (28).
THE REGULATION OF BLOOD FLOW

Endotheliumdependent vasodilation occurs via the synthesis of nitric oxide (NO) and vasodilating
prostaglandins (PGs; i.e., prostacyclin) (19) or endotheliumderived hyperpolarization (18, 20). In young
healthy humans, the contribution of NO and PGs is minimaltomodest during mild and moderateintensity
isolated muscle mass exercise (4, 10, 41, 51). Beyond NO and PGs, the endothelium is capable of
stimulating vascular smooth muscle hyperpolarization leading to decreased calcium influx through voltage
gated calcium channels and thus vascular smooth muscle cell relaxation and subsequent vasodilation. Often,
the endothelial cell layer itself also hyperpolarizes and this can stimulate the direct (through myoendothelial
projections) or indirect (through efflux of a “factor”) hyperpolarization of vascular smooth muscle cells (36).
In animals models, prevention of hyperpolarization (22, 39) or ascending vasodilation (54), to which
hyperpolarization largely contributes (16), attenuates contractioninduced hyperemia. A few studies in
humans have addressed candidate hyperpolarizing pathways including cytochrome P450 metabolites (25),
calciumactivated potassium (KCa) channels (41), and adenosine triphosphate (ATP)sensitive potassium
channels (KATP) (50); however, the reductions in steadystate exercise hyperemia by these inhibitors have
been minimal or nonexistent and the contribution of these pathways to the onset hyperemia has not been
explored.
Recently, we have shown that K+stimulated hyperpolarization of resistance vessels via the activation of
inwardly rectifying potassium (KIR) channels and Na+K+ATPase contributes to a large portion (∼50%) of
the hyperemic response following a single muscle contraction in the human forearm and, combined with NO
and PGs, accounts for nearly all (∼80%) of the immediate total vasodilator response (7). In addition,
activation of KIR channels underlies the majority of ATPmediated vasodilation (6), a substance proposed to
be involved in vascular regulation during exercise in humans (21, 32, 46). Lastly, inhibition of KIR channels
significantly reduces the immediate peak reactive hyperemic response to temporary muscle ischemia and
combined inhibition of KIR channels and Na+K+ATPase nearly abolishes the total [area under the curve
(AUC)] response (12). Thus pathways capable of hyperpolarizing vascular smooth muscle and/or endothelial
cells are attractive candidates for obligatory signaling at the onset and during continued muscle contractions.
With this collective information as a background, the purpose of the present experiment was to test the
hypothesis that activation of KIR channels and Na+K+ATPase contributes to exercise hyperemia both at
the onset of muscle contractions and during steadystate exercise in humans. Furthermore, we sought to
determine whether there would be a combined role for NO and PGs after inhibiting activation of KIR
channels and Na+K+ATPase. Finally, we performed a followup study based on recent observations from
our laboratory to identify whether there was an independent role of KIR channel activation in this complex
response in humans.
METHODS
Subjects

With Colorado State University Institutional Review Board approval and after written informed consent, a
total of 27 young healthy adults [protocol 1: 7 men, 4 women; age = 23 ± 1 yr; weight = 71.6 ± 2.6 kg;
height = 172 ± 3 cm; body mass index = 24.1 ± 0.7 kg/m2; forearm volume (FAV) = 848 ± 41 ml; protocol
2: 4 men, 4 women; age = 24 ± 2 yr; weight = 69.0 ± 3.0 kg; height = 173 ± 3 cm; body mass index = 23.1
± 0.8 kg/m2; FAV = 811 ± 62 ml; protocol 3: 5 men, 3 women; age = 21 ± 1 yr; weight = 71.0 ± 4.2 kg;
height = 176 ± 2 cm; body mass index = 23.0 ± 1.0 kg/m2; FAV = 945 ± 93 ml; means ± SE] participated in
the present study. All subjects were sedentary to moderately active, nonsmokers, nonobese, normotensive
(resting blood pressure <140/90 mmHg), and not taking any medications. Studies were performed after an
overnight fast and 24h abstention from caffeine and exercise with subjects in the supine position with the
experimental arm abducted to 90° and slightly elevated above heart level upon a tiltadjustable table. Female

subjects were studied during the early follicular phase of their menstrual cycle or placebo phase of oral
contraceptive use to minimize any potential cardiovascular effects of sexspecific hormones.
Arterial Catheterization, Arterial Blood Pressure, and Heart Rate

A 20gauge, 7.6cm catheter was placed in the brachial artery of the nondominant arm under aseptic
conditions after local anesthesia (2% lidocaine) for local administration of study drugs and blood sampling.
The catheter was connected to a threeport connector as well as a pressure transducer for mean arterial
pressure (MAP) measurement and continuously flushed at 3 ml/h with heparinized saline. The two side ports
were used for drug infusions (11, 34). Heart rate (HR) was determined using a threelead electrocardiogram
(ECG; Cardiocap/5, DatexOhmeda, Louisville, CO).
Forearm Blood Flow and Vascular Conductance

A 12MHz lineararray ultrasound probe (Vivid 7; General Electric, Milwaukee, WI) was used to determine
brachial artery mean blood velocity (MBV) and brachial artery diameter. The probe was securely fixed to the
skin over the brachial artery proximal to the catheter insertion site as previously described (11). For blood
velocity measurements, the probe insonation angle was maintained at <60° and the frequency used was 5
MHz. The Doppler shift frequency spectrum was analyzed via a Multigon 500M TCD (Multigon Industries,
Mt. Vernon, NY) spectral analyzer from which mean velocity was determined as a weighted mean of the
spectrum of Doppler shift frequencies. In protocols 1 and 3, brachial artery diameter measurements were
made in duplex mode from images recorded on a VHS tape at enddiastole and between contractions (in
triplicate) during rest and at 6, 12, 24, 60, 90, 120, 180, 240, and 300 s of exercise. All measurements were
made by the same operator. An exponential line of best fit was generated for these data, and diameters were
extrapolated from this function at relevant MBV time points. We utilized this approach in an attempt to
minimize the effect of random diameter measurement error on blood flow (49). In protocol 2, diameter
measurements were made in triplicate at rest and the end of exercise. Forearm blood flow (FBF) was then
calculated as:

FBF = MBV × π(brachial artery diameter/2)

2

× 60,

where the FBF is in ml/min, the MBV is in cm/s, the brachial diameter is in cm, and 60 was used to convert
from ml/s to ml/min. Forearm vascular conductance (FVC) was calculated as (FBF/MAP) × 100 and
expressed as ml·min−1·100 mmHg−1. All studies were performed in a cool (20–22°C) temperature
controlled environment with a fan directed toward the forearm to minimize the contribution of skin blood
flow to forearm hemodynamics.
Rhythmic Handgrip Exercise

Maximal voluntary contraction (MVC; all subjects mean 41 ± 2 kg, range 22–67 kg) was determined for the
experimental arm as the average of three maximal squeezes of a handgrip dynamometer (Stoelting, Chicago,
IL) that were within 3% of each other. Forearm exercise during the trials was performed with weight
corresponding to 10% MVC (mean 4.1 ± 0.2 kg, range 2.2–6.7 kg) attached to a pulley system and lifted 4–
5 cm over the pulley at a duty cycle of 1s contraction2s relaxation (20 contractions/min) using both visual
and auditory feedback to ensure the correct timing as described previously (11, 34). We chose this mild
intensity rhythmic handgrip exercise to limit the contribution of systemic hemodynamics and reflex activation
of the sympathetic nervous system on exercise hyperemia (42, 52). Under these conditions, changes in
cardiac output are not necessary to achieve the forearm hyperemia observed (42), and thus our experimental
model isolates the effects of muscle contractions on local vascular control mechanisms. Additionally,

previous studies in our laboratory have determined that MVC is not affected by any of the vasoactive
substances, particularly barium chloride and ouabain, administered in these studies (7).
Vasoactive Drug Infusion

All vasoactive drug infusions occurred via the brachial artery catheter to create a local effect in the forearm,
and saline was utilized as a control infusate. Specific timing and duration of infusions are provided in
Experimental Protocols.
To inhibit select hyperpolarizing vasodilator mechanisms (6, 12), ouabain octahydrate (Na+K+ATPase
inhibitor; Sigma 03125, St. Louis, MO) was infused at 2.7 nmol/min in combination with barium chloride
(BaCl2; KIR channel inhibitor; 10% wt/vol BDH3238; EMD Chemicals, Gibbstown, NJ) at 0.9 μmol·dl
FAV−1·min−1 with a minimum dose of 8 μmol/min to a maximum dose of 10 μmol/min. This dose of BaCl2
is the same as we have previously utilized in hyperemic conditions and, importantly, did not impact forearm
vasodilation to the endotheliumindependent vasodilator sodium nitroprusside (12). Ouabain and BaCl2 were
prepared in saline and confirmed sterile and free of fungus/endotoxin and particulate matter with a standard
microbiology report (JCBAnalytical Research Labs, Wichita, KS) before use.
To block additional endotheliumdependent vasodilator pathways of interest, we administered NG
monomethylL arginine [L NMMA; NO synthase (NOS) inhibitor; Clinalfa/Bachem, Weil am Rhein,
Germany] to inhibit the production of NO in combination with ketorolac [nonselective cyclooxygenase
(COX) inhibitor; Hospira, Lake Forest, IL] to inhibit the synthesis of PGs. The doses of L NMMA and
ketorolac were 5 mg/min and 1,200 μg/min, respectively. We have previously demonstrated these doses to
be effective during a similar exercise protocol (11, 14, 51). Forearm volume used for normalization for
specific vasoactive drugs was determined from regional analysis of whole body dualenergy Xray
absorptiometry scans (QDR series software; Hologic, Bedford, MA).
Experimental Protocols

Experimental protocols are presented in Fig. 1. The main purpose of
protocol 1 was to determine the effect of inhibiting KIR channel and Na+K+ATPase activation (via BaCl2
and ouabain) alone, and in combination with NOSCOX blockade (via L NMMA and ketorolac,
respectively) on the hyperemia that occurs at the onset of repeated muscle contractions. To do this, subjects
performed 10% MVC rhythmic handgrip exercise for 5 min in control conditions (trial 1; saline), following
combined infusion of BaCl2 and ouabain (trial 2), and following combined infusion of BaCl2, ouabain, L 
NMMA, and ketorolac (trial 3). Previously, we have observed acute fluctuations in resting vascular tone
with BaCl2 and ouabain infusion (7); thus we infused BaCl2 and ouabain together for 3 min (preexercise)
and then stopped infusion to obtain accurate resting blood flow for 30–60 s. After resting blood flow was
obtained, subjects then began muscle contractions. This method of drug infusion was previously used by our
laboratory and proven effective at significantly reducing the blood flow response to a single muscle
contraction (7). This approach was performed for all trials in this protocol to appropriately quantify resting
blood flow and the rapid hyperemia in response to exercise.
Protocol 1: onset exercise hyperemia.

In trial 1, saline was infused for 3 min before the start of resting blood flow measures. A single contraction
(10% MVC) was performed at 30, 60, and 90 s of this infusion to facilitate delivery of the infusion to the
vasculature of the muscle fibers recruited for this type of contraction (7). After saline infusion stopped,
resting blood flow measures were made for 30–60 s and the subject was then instructed to begin the 5 min of
contractions. Beattobeat blood flow was measured throughout the entire 5min exercise protocol. Subjects
rested comfortably for 20 min before the start of the next exercise trial. Trials 2 and 3 were similar; however,
the infusions differed. In trial 2, ouabain was infused for 15 min and BaCl2 was added for the final 3 min

before the start of resting blood flow measures. In trial 3, ouabain and BaCl2 were infused as in trial 2, and
L NMMA and ketorolac were added for the final 5 min before the start of resting blood flow measures.
Based on our observations in protocol 1 (see RESULTS), we
believed it was necessary to perform a second protocol where we continued infusion of our inhibitors
throughout the muscle contractions to determine whether we had underestimated the effect of our blockers
on steadystate exercise hyperemia in protocol 1. The trials in protocol 2 mimicked those of protocol 1
(control, BaCl2 + ouabain, and BaCl2 + ouabain + L NMMA + ketorolac) with the key experimental
difference being that all inhibitors were infused for a similar duration at rest (preexercise) but then continued
throughout the entire 5min exercise duration. Forearm hemodynamics in this protocol were assessed in the
final minutes of drug infusions at rest and in the final minute of exercise (minute 5).
Protocol 2: steadystate exercise hyperemia.

Given that we have shown inhibition of KIR channels alone
can have a significant effect on pharmacological and ischemiainduced hyperemia and may explain the
effects of combined BaCl2 and ouabain (6, 12), we designed a followup protocol to determine whether
there was an independent contribution of KIR channels to onset and steadystate exercise hyperemia. In our
previous studies, we did not observe fluctuations in resting vascular tone during BaCl2 infusions alone (6,
12), and thus here we continuously infused the inhibitors throughout rest and the duration of muscle
contractions so as not to underestimate any steadystate effects. Protocol 3 consisted of three trials: control
(saline), KIR channel inhibition (BaCl2), and combined KIR channel and Na+K+ATPase inhibition (BaCl2
+ ouabain). Each trial consisted of a resting period followed by 5 min of rhythmic handgrip exercise at 10%
MVC.
Protocol 3: independent KIR channel inhibition.

Data Acquisition and Analysis

Data were collected and stored on a computer at 250 Hz and were analyzed offline with signalprocessing
software (WinDaq; DATAQ Instruments, Akron, OH). MAP was determined from the arterial pressure
waveform. For protocols 1 and 3, FBF and MAP were analyzed in 3s bins that corresponded to each
contraction:relaxation (1:2 s) cycle. This type of analysis was carried out for the first 3 min, and 30s
averages were used at minutes 4 and 5 of exercise. In the case that the MBV signal quality obtained during a
3s cycle was altered due to operator error, a mathematical average of the preceding and the MBV of the
subsequent bins was used. This occurred in <2% of all bins analyzed. HR was determined at rest and each
minute of exercise thereafter.
In protocols 1 and 3, the total exerciseinduced hyperemic and vasodilator responses were calculated as the
sum of FBF and FVC, respectively, above baseline for 30, 60, 120, 180, 240, and 300 s of exercise (AUC).
In protocol 2, the last 30 s of exercise was averaged to represent steadystate FBF and FVC.
To quantify the impact of vasoactive drugs in each protocol on FBF, the magnitude of inhibition of exercise
hyperemia was calculated as:

(FBF inhibition − FBF control) / (FBF control) × 100.

Changes in FVC, as well as AUC, were calculated in a similar manner.
Statistics

Data are presented as means ± SE. In all protocols, twoway repeatedmeasures ANOVA (time point × drug
condition) and post hoc pairwise comparisons were completed and StudentNewmanKeuls pairwise tests
were used to analyze relevant timeaveraged data. Paired Student's ttests were used to analyze the calculated

magnitude of inhibition (percent change) in steadystate hemodynamics between drug conditions.
Significance was set a priori at P < 0.05.
RESULTS
For all protocols, systemic hemodynamics (HR and MAP) were largely unchanged throughout the trials and
under all conditions. Some small (2–3 mmHg and 2–4 beats/min) but statistically significant differences in
MAP and HR, respectively, were observed in the condition of prior BaCl2 + ouabain + L NMMA +
ketorolac infusion vs. control (Tables 1, 2, and 3).
Protocol 1: Onset Exercise Hyperemia

In control (saline) conditions, FBF increased rapidly from rest (34 ± 3 ml/min) in response to muscle
contractions (Fig. 2A). In trial 2, combined inhibition of KIR channels and Na+K+ATPase (via infusion of
BaCl2 + ouabain that was stopped before resting measures and the start of exercise) had no effect on resting
FBF (30 ± 3 ml/min) but significantly attenuated FBF for the first 2 min of exercise (Fig. 2B). FBF at
minutes 3, 4, and 5 was not different compared with control. Additionally, in trial 2, the total hyperemic
response was significantly attenuated from control and this effect was more pronounced earlier in the
exercise bout (30 s: −49 ± 5%; 60 s: −34 ± 5%; 120 s: −20 ± 5%; 180 s: −13 ± 4%; 240 s: −10 ± 4%; 300 s:
−8 ± 3%). In trial 3, FBF for the first 15 s after exercise onset was reduced compared with trial 2; however,
FBF was not different thereafter until minute 5 of exercise where FBF was reduced ∼8% from control (
Fig. 2B). When the total hyperemic response was quantified, L NMMA and ketorolac only had an additional
effect at 30 and 300 s (%Δ from control: 30 s: −65 ± 2%; 60 s: −40 ± 3%; 120 s: −23 ± 4%; 180 s: −15 ±
4%; 240 s: −14 ± 4%; 300 s: −14 ± 4%). Changes in FVC paralleled those observed in FBF (Table 1).
Protocol 2: SteadyState Exercise Hyperemia

After 5 min of exercise, steadystate FBF (Fig. 3A) and FVC (Fig. 3B) were significantly lower with
continuous infusion of BaCl2 and ouabain throughout muscle contractions (trial 2: 133 ± 15 ml/min; 140 ±
15 ml·min−1·100 mmHg−1) than in control conditions (trial 1: 167 ± 17 ml/min; 194 ± 18 ml·min−1·100
mmHg−1). In trial 3, inhibiting NO and PG synthesis in addition to KIR channels and Na+K+ATPase
resulted in a further attenuation of exercise hyperemia and vasodilation compared with control conditions (
Fig. 3, A and B). Compared with control, BaCl2 and ouabain reduced steadystate FBF and FVC −20 ± 3
and −28 ± 2%, respectively, and the addition of L NMMA and ketorolac had a total impact of −29 ± 3 and
−40 ± 3% on FBF and FVC, respectively.
Protocol 3: Independent KIR Channel Inhibition

In control (saline) conditions, FBF increased rapidly from rest (34 ± 5 ml/min) in response to muscle
contractions (Fig. 4A). In trial 2, continuous infusion of BaCl2 throughout the trial did not alter resting FBF
(26 ± 3 ml/min) but significantly attenuated FBF for all 5 min of exercise (Fig. 4B). The total hyperemic
response was significantly attenuated with BaCl2 (%Δ from control: 30 s: −64 ± 6%; 60 s: −60 ± 7%; 120 s:
−48 ± 7%; 180 s: −42 ± 7%; 240 s: −38 ± 6%; 300 s: −36 ± 6%). In trial 3, continuous infusion of BaCl2 +
ouabain did not affect resting FBF (31 ± 3 ml/min). Absolute FBF at the onset of exercise, although
significantly lower than control conditions, was not different than the BaCl2 alone condition (Fig. 4B). A
similar pattern was evident when the total hyperemic response was quantified and the reduction from control
conditions was calculated (30 s: −54 ± 10%; 60 s: −56 ± 8%; 120 s: −47 ± 5%; 180 s: −42 ± 5%, 240 s: −45
± 4%; 300 s: −46 ± 5%). Again, changes in FVC paralleled those observed in FBF (Table 3). The percent
reductions in FBF and FVC from control steadystate exercise levels (minute 5) were similar in magnitude
(∼30%) to those observed in protocol 2 when both BaCl2 + ouabain were continuously infused throughout
exercise.

DISCUSSION
The primary purpose of the present study was to determine the contribution of activation of KIR channels
and Na+K+ATPase to exercise hyperemia at the onset of muscle contractions and during the steadystate
portion of the blood flow response and to determine whether prior inhibition of these pathways revealed a
role for NO and PGs. We then followed up our initial findings and further sought to identify if there was an
independent role for KIR channel activation in exercise hyperemia. The primary novel findings of the present
study are as follows. First, combined inhibition of KIR channels and Na+K+−ATPase significantly
attenuates onset of exercise hyperemia following repeated muscle contractions (protocol 1) and this is largely
due to KIR channel activation (protocol 3). Additionally, in line with prior findings in the human forearm,
NO and PGs do not play a significant role in the onset of the response except potentially for the initial 15 s
(protocol 1). Second, we demonstrate for the first time in humans a significant attenuation of steadystate
exercise hyperemia with inhibition of activation of KIR channels and Na+K+ATPase and similar to the
onset, this is primarily due to activation of KIR channels (protocols 2 and 3). Interestingly, prior inhibition of
KIR channels and Na+K+ATPase reveals a significant role for NO and PGs in mediating steadystate
exercise hyperemia that has not been previously observed in this model of mildtomoderate intensity
rhythmic handgrip exercise (protocol 2). Our collective findings indicate a novel role for KIR channel
activation in exercise hyperemia in humans, and this contribution is greater at exercise onset (∼50%)
compared with steadystate conditions (∼30%).
Onset Exercise Hyperemia: Contributing Signaling Pathways (Protocols 1 and 3)

At the onset of exercise, there is a rapid increase in blood flow that occurs immediately upon muscular
relaxation, and recent evidence indicates this is largely due to rapid local vasodilation (5, 7, 31). With
repeated muscle contractions, this increase in blood flow continues in a biphasic manner comprised of an
initial rapid increase that plateaus by ∼5–7 s and a second, slower phase that begins ∼20 s after the onset of
exercise and continues in an intensitydependent manner until steadystate hyperemia has been achieved (49,
60). In the present study, we observe similar dynamic characteristics in the hyperemic response to mild
intensity handgrip exercise in control conditions (Fig. 2A). Previous studies in the human forearm
demonstrated that inhibition of NO or PGs does not impact the rapid onset of exercise hyperemia (56, 57)
nor does antagonism of muscarinic receptors (56) that would be bound by acetylcholine either from an
endothelial source (38) or spillover from the motor neuron junction (61). Studies in animals suggest that
during continuous muscle contractions distal resistance arterioles within the active tissue relax (62) and this
dilation is conducted upstream to the level of the feed arteries (53). Hyperpolarization of endothelial and
vascular smooth muscle cells is known to contribute more robustly to distal vessel vasodilation as opposed to
vasodilator autocoids such as NO and PGs (48, 55) and is capable of stimulating conducted vasodilation,
whereas, in general, NO and PGs do not (16, 26). Recently, we demonstrated that activation of KIR
channels and Na+K+ATPase contributes to the total vasodilation following a single muscle contraction (7),
the first such observation in humans. In the present study, we determined what role these pathways have in
the onset of hyperemia in response to repeated muscle contractions.
When BaCl2 and ouabain were infused before contractions to inhibit KIR channels and Na+K+ATPase,
respectively, there was a significant attenuation of the initial hyperemic response for the first 2 min of
exercise (Fig. 2B) and the findings of protocol 3 suggest this is due to activation of KIR channels (Fig. 4). In
protocol 1, beyond 2 min, there was no longer a significant effect on the absolute level of blood flow;
however, the initial impact on the hyperemia was of large enough magnitude to affect the total (AUC)
hyperemic response through 4 min of exercise. In this protocol, due to fluctuations in resting blood flow that
we have observed during infusion of BaCl2 and ouabain in our laboratory (7), we stopped drug infusions at
rest then obtained blood flow measures for 30–60 s before the start of muscle contractions. Utilizing this

method allowed us to appropriately quantify resting FBF and the rapid blood flow responses to muscle
contraction; however, because drugs were not coinfused throughout muscle contractions, we may have
underestimated the impact of inhibition on steadystate hyperemia. Given our possible underestimation, we
sought to more directly address a role for activation of KIR channels and Na+K+ATPase during steady
state hyperemia in protocol 2 where all inhibitors were coinfused during muscle contractions (see section
below).
Several lines of evidence suggest that there is crossover between the various vasodilator pathways and that,
in the presence of inhibition of one pathway, another may compensate to preserve blood flow and oxygen
delivery, particularly during muscle activation or decreased arterial oxygen content (25, 37, 59). Thus we
investigated whether in the presence of inhibition of KIR channels and Na+K+ATPase, there would be a
role for NO and PGs, despite prior evidence suggesting they do not contribute to initial exercise hyperemia
in the human forearm (56, 57). Combined infusion of L NMMA and ketorolac to enzymatically inhibit the
production of NO and PGs, respectively, reduced FBF beyond that which occurred with BaCl2 + ouabain at
the start of forearm contractions (Fig. 2B). However, this further impairment diminished rapidly over time,
and by 30 s there was no longer a significant reduction in FBF from the BaCl2 + ouabain condition.
Similarly, there was minimal additional effect of NO and PG inhibition on the total hyperemic response. It is
possible that the reduction in resting blood flow during combined NO and PG inhibition attributed to the
initial and brief reduction in exercise hyperemia, similar to prior observations of lower resting blood flow and
slower forearm blood flow response times to handgrip exercise when the arm was positioned above vs.
below heart level (57). In the presence of BaCl2 + ouabain + L NMMA + ketorolac, muscle blood flow was
still able to increase rapidly and achieve levels significantly greater than rest and near steadystate levels by 3
min of exercise, indicating redundant vasodilator signals, even from the onset of muscle contractions.
SteadyState Exercise Hyperemia: Contributing Signaling Pathways (Protocols 2 and 3)

To date, multiple studies have attempted to identify the various vasodilator pathways involved in exercise
hyperemia and most have focused on the steadystate portion of the response (13, 28, 45). Steadystate
muscle blood flow is thought to reflect a homeostatic balance between oxygen delivery via increases in
blood flow and oxygen demand of the contracting muscle (43). In the human forearm, the results of previous
studies have been rather unimpressive in terms of the magnitude of reduction in muscle blood flow
consequent to vasodilator inhibition. In fact, combined inhibition of NO and PGs, two important
endotheliumdependent dilators, does not impact the rest to steadystate muscle blood flow response (10, 51).
Given animal studies that suggested an important role for the endothelium (2, 44) and particularly for
conducted hyperpolarizing stimuli (39, 54) in exercise hyperemia and the lack of involvement of NO and
PGs, we wanted to address the role of resistance vessel hyperpolarization in muscle blood flow control
during exercise in humans.
One issue with attempting to address hyperpolarizing pathways in humans is a lack of specific antagonists
and agonists of the proposed pathways involved in initiating and conducting hyperpolarization in the
vasculature. Additionally, in human studies, it is not possible to directly measure membrane potential or
identify the cell type (endothelial and vascular smooth muscle) that may hyperpolarize. Previously, we have
demonstrated that combined administration of ouabain and BaCl2 can abolish KClmediated vasodilation, a
stimulus for direct vascular smooth muscle cell hyperpolarization (6). In the present study we used this
established pharmacology (6, 7, 12) to test the role of vascular hyperpolarization in muscle blood flow
regulation during continued muscle contractions.
Due to the observed fluctuations in resting blood flow in the present studies and in our past experience with
ouabain and BaCl2 (6, 7), in protocol 1 where we were focused on capturing the onset of exercise
hyperemia, we did not coinfuse these inhibitors during contractions. However, when we did not observe a

significant effect during steadystate exercise (Fig. 1), we questioned whether there was “washout” of our
inhibitors as blood flow increased or a reduction in effectiveness over time. Subsequently, we performed
studies in protocol 2 in which we coinfused our inhibitors throughout muscle contractions as is more typical
of our approach for these types of exercise studies (10, 11). Furthermore, given these fluctuations appeared
to be due to ouabain, in protocol 3 where we assessed an independent impact of BaCl2 we also continuously
infused our pharmacology throughout the entire rest and exercise period. Under these conditions of
continuous inhibition, we do in fact observe a significant contribution of KIR channels and Na+K+ATPase
to steadystate exercise hyperemia (Fig. 3) and this is specifically due to a role of KIR channel activation
alone (Fig. 4; range from both protocols 20–30%).
Interestingly, combined inhibition of NO and PGs in addition to hyperpolarization mediated by KIR channel
and Na+K+ATPase activation resulted in a statistically significant further attenuation of steadystate muscle
blood flow and vascular conductance in protocol 2 (Fig. 3). This finding is in contrast with the lack of a
combined role for NO and PGs in the human forearm in previous studies (10, 15, 51) but highlights the
ability of vasodilator pathways to compensate for one another, a phenomenon that has been observed in a
variety of previous studies (25, 37, 59). It is important to emphasize the magnitude of the effect of combined
inhibition of KIR channels, Na+K+ATPase, and NO and PGs on FBF and FVC during steadystate
exercise. A 40% reduction in forearm vasodilation (FVC) is profound, particularly in a small muscle mass
such as the forearm that typically is minimally affected following pharmacological inhibition of vasodilator
pathways. Furthermore, this change approaches the observed effects of completely inhibiting conducted
vasodilation (∼45% reduction in contractioninduced hyperemia) in animal models (54) providing an
additional context for our findings.
Potential Stimuli for Signaling Through KIR channels, Na+K+ATPase, and NO and PGs During
Exercise

As previously stated, there are a variety of substances that can stimulate hyperpolarization of the vasculature,
both endothelium dependent and independent. One candidate substance is the K+ ion, as interstitial K+
increases as a result of muscle contractions (1, 18, 24, 30) and can also be released as an endothelialderived
hyperpolarizing factor (18). Agonist binding to receptors on endothelial cells can cause intracellular calcium
changes that stimulate small and intermediateconductance KCa channels to open and K+ to efflux into the
interstitial space or microdomain signaling complexes at the physical intersection of vascular smooth muscle
and endothelial cells (35). In animal models where these small and intermediateconductance KCa channels
can be specifically inhibited, a significant attenuation in contractioninduced hyperemia is observed (39).
While the K+ ion would not account for the compensatory involvement of NO and PG during steadystate
exercise (6), it could be involved in directly stimulating both KIR channels and Na+K+ATPase (6, 18)
ultimately resulting in vascular smooth muscle cell hyperpolarization, thus contributing to both the onset and
steadystate levels of exercise hyperemia.
Another potential stimulus for hyperpolarization of endothelial and vascular smooth cells is ATP, a potent
vasoactive molecule released from endothelial and red blood cells in response to deoxygenation,
hypercapnia, and mechanical stresses that increases in plasma samples of blood draining contracting skeletal
muscle tissue (3, 8, 21, 32, 58). ATP causes profound vasodilation that is endothelium dependent (17), and
we have determined in humans the primary underlying signaling mechanism is activation of KIR channels
(6). Additionally, we have demonstrated a modest component of ATPmediated vasodilation occurs through
NO and PG synthesis (9) and thus particularly during steadystate exercise where a significant role for NO
and PGs is revealed when hyperpolarization is inhibited, ATP may also serve as a potential stimulus for
these pathways.
Experimental Considerations

Our group has recently utilized the pharmacological approach of local BaCl2 and ouabain infusions to inhibit
hyperpolarization stimulated by KIR channel and Na+K+ATPase activation, respectively (6, 7, 12). While
these inhibitors are safe for use, given that they are not used clinically, we attempt to limit the total number of
subjects exposed to these agents and the total dose given to any one subject. Therefore, we have not repeated
control experiments within this protocol to demonstrate effective inhibition of hyperpolarizationmediated
(KCl) vasodilation, preserved vasodilator capacity [to endotheliumdependent (acetylcholine) and
endotheliumindependent (sodium nitroprusside) agonists], and preserved maximal force production (6, 7).
Similarly, given our extensive use of L NMMA and ketorolac (6, 7, 9–12) and various tests of efficacy (14,
51), we have not repeated those control studies within this experiment. When all four inhibitors (BaCl2,
ouabain, L NMMA, and ketorolac) are administered, vasodilation to sodium nitroprusside remains preserved
(12). It is possible that our dose of BaCl2 may not be selective for KIR channels and inhibits other potassium
channels, specifically KATP channels (27). However, given that previously there was no significant effect of
inhibiting KATP channels during steadystate exercise in an identical experimental model (50), we do not feel
this changes our primary conclusions. Furthermore, inhibition of other potential pathways leading eventually
to vascular smooth muscle cell hyperpolarization such as cytochrome P450 metabolites (25) and large
conductance KCa channels (41) has no impact on exercise hyperemia, adding to the support for our specific
impact of BaCl2 on KIR channels.
The forearm model, while advantageous for many reasons, also has some inherent limitations. We
acknowledge that the muscle mass engaged in rhythmic handgrip exercise is relatively small and
extrapolating our results to more traditional modes of whole body exercise would need to be done cautiously.
It may be desirable to test ideas related to the role of hyperpolarization via KIR channel activation in
regulating vascular control during larger muscle mass exercise that engage the sympathetic nervous system to
assess the influence of these pathways on the interaction with sympathetic vasoconstriction and overall blood
pressure regulation; however, safety concerns of systemic administration of BaCl2 in doses suitable to
appropriately inhibit KIR channels preclude this at the present time.
Conclusions

Continuous skeletal muscle contractions result in a rapid and significant rise in muscle blood flow to deliver
oxygen to meet the increased metabolic need of the tissue. The regulation of muscle blood flow during
exercise is a complex response and given the strong relation among muscle blood flow, oxygen delivery, and
exercise capacity in health and disease, there is great interest in understanding the various vasodilator signals
that contribute to this response. Here, we demonstrate for the first time in humans that KIR channel activation
significantly contributes to the hyperemia observed at the onset of and during steadystate muscle
contractions. Additionally, NO and PGs have at most a modest contribution to the initial (10–15 s) rise in
muscle blood flow, and interestingly, in the presence of inhibition of KIR channels and Na+K+ATPase, we
reveal a role for these dilators during steadystate exercise hyperemia, an observation that was not previously
made in this experimental model. The primary stimuli for activation of KIR channels during muscle
contractions remain unclear at this time, but the K+ ion and circulating ATP are two likely candidates. Future
work will be needed to definitively identify these stimuli and, furthermore, to determine what role these
pathways may play in the reduced muscle perfusion often observed with aging and disease.
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Figures and Tables
Fig. 1.

Experimental timeline. Three trials were performed in all protocols and trial 1 (T1) always consisted of saline infusion as a
control condition. In protocols 1 (A) and 2 (B), trial 2 (T2) consisted of the combined infusion of barium chloride [BaCl2;
inwardly rectifying potassium (KIR) channel inhibitor] and ouabain (Na+K+ATPase inhibitor) and trial 3 (T3) consisted
of the combined infusion of BaCl2, ouabain, NG monomethylLarginine (LNMMA; to inhibit nitric oxide synthesis) and
ketorolac (to inhibit prostaglandin synthesis). During the loading period of drug infusions at rest, 3 single contractions were
performed to facilitate drug delivery. In protocol 1, to avoid previously observed fluctuations in baseline hemodynamics,
drugs were stopped before resting measures were made and exercise commenced. Measurements were made at rest, at the
onset of 10% maximal voluntary contraction (MVC) rhythmic handgrip exercise, and throughout the 5min bout of
exercise. In protocol 2, drugs were continuously coinfused throughout rest and the entire handgrip exercise trial. C: in
protocol 3, drugs were also continuously infused and to determine the independent effect of KIR channel inhibition in trial
2, BaCl2 alone was infused and in trial 3, combined BaCl2 and ouabain were administered.
Table 1.

Protocol 1: forearm and systemic hemodynamics
Time Point/Condition

FVC, ml·min

−1

·100 mmHg

−1

‡
§
MAP, mmHg HR, beats/min

Rest
Control

36.4 ± 3.4

93 ± 2

56 ± 3

BaCl2 + ouabain

31.8 ± 2.3

94 ± 3

57 ± 4

96 ± 2

53 ± 3

BaCl2 + ouabain + LNMMA + ketorolac 25.8 ± 2.5
Exercise minute 1

*†

Control

140.2 ± 9.8

94 ± 3

61 ± 4

96 ± 3

59 ± 4

98 ± 2

57 ± 4

94 ± 2

59 ± 4

96 ± 2

59 ± 3

97 ± 2

56 ± 4

94 ± 3

57 ± 5

96 ± 3

59 ± 4

97 ± 2

57 ± 3

95 ± 2

60 ± 4

95 ± 3

59 ± 3

97 ± 2

57 ± 3

166.0 ± 15.3

95 ± 2

59 ± 4

157.1 ± 10.3
*
BaCl2 + ouabain + LNMMA + ketorolac 145.4 ± 9.2

95 ± 2

59 ± 4

97 ± 2

58 ± 4

*

BaCl2 + ouabain

109.3 ± 7.6
*†
BaCl2 + ouabain + LNMMA + ketorolac 99.5 ± 5.7
Exercise minute 2
Control

151.3 ± 11.9
*
BaCl2 + ouabain
134.9 ± 9.6
*
BaCl2 + ouabain + LNMMA + ketorolac 128.5 ± 7.9
Exercise minute 3
Control

150.2 ± 9.8

BaCl2 + ouabain

139.6 ± 8.3

BaCl2 + ouabain + LNMMA + ketorolac 134.7 ± 9.9

*
*

Exercise minute 4
Control

155.6 ± 10.8

BaCl2 + ouabain

147.5 ± 8.7

BaCl2 + ouabain + LNMMA + ketorolac 142.7 ± 10.3

*

Exercise minute 5
Control
BaCl2 + ouabain

Values are means ± SE; n = 11 subjects. FVC, forearm vascular conductance; HR, heart rate; MAP, mean
arterial pressure.
*

P < 0.05 vs. control.
P < 0.05 vs. BaCl2 + ouabain.
‡
MAP: main effect of condition [BaCl2 + ouabain + NGmonomethylL arginine (L NMMA) + ketorolac vs.
control; P < 0.05].
§
HR: main effect of condition (BaCl2 + ouabain + L NMMA + ketorolac vs. control and vs. BaCl2 +
ouabain, P < 0.05); main effect of time point (minutes 1–5 vs. rest; P < 0.05); no significant interaction (P =
0.35).
†

Table 2.

Protocol 2: systemic hemodynamics
Time Point/Condition

MAP,* mmHg HR,† beats/min

Rest
Control

84 ± 2

56 ± 3

BaCl2 + ouabain

90 ± 3

54 ± 3

BaCl2 + ouabain + LNMMA + ketorolac 94 ± 4

56 ± 3

Steadystate exercise (minute 5)
Control

86 ± 3

60 ± 3

BaCl2 + ouabain

95 ± 2

60 ± 3

BaCl2 + ouabain + LNMMA + ketorolac 100 ± 3

59 ± 3

Values are means ± SE; n = 8 subjects.
*

MAP: main effect of time point (exercise vs. rest; P < 0.05) and condition (all conditions different; P <
0.05); no significant interaction (P = 0.07).
†
HR: main effect of time point (exercise vs. rest; P < 0.01); no significant main effect of condition (P = 0.32)
or interaction (P = 0.47).
Table 3.

Protocol 3: forearm and systemic hemodynamics
Time Point/Condition

FVC, ml·min

−1

·100 mmHg

−1

‡
MAP, mmHg HR,§ beats/min

Rest
Control

36.5 ± 5.2

93 ± 4

62 ± 5

BaCl2

27.6 ± 3.7

95 ± 3

61 ± 5

BaCl2 + ouabain 31.8 ± 3.7

97 ± 3

59 ± 5

93 ± 3

64 ± 5

94 ± 3

62 ± 6

97 ± 3

62 ± 6

94 ± 3

64 ± 6

96 ± 3

63 ± 5

98 ± 3

62 ± 5

94 ± 3

65 ± 6

97 ± 2

64 ± 6

100 ± 2

64 ± 5

94 ± 3

66 ± 6

94 ± 3

64 ± 6

100 ± 2

64 ± 6

94 ± 3

64 ± 6

95 ± 3

64 ± 6

101 ± 2

65 ± 6

Exercise minute 1
Control

135.4 ± 20.7
*
BaCl2
73.2 ± 16.2
*
BaCl2 + ouabain 74.9 ± 11.9
Exercise minute 2
Control

157.6 ± 20.3
*
BaCl2
99.9 ± 18.1
*
BaCl2 + ouabain 97.3 ± 12.4
Exercise minute 3
Control
BaCl2

162.6 ± 17.6
110.9 ± 17.1

BaCl2 + ouabain 103.6 ± 12.2

*
*

Exercise minute 4
Control
BaCl2

169.3 ± 18.3
119.1 ± 15.9

BaCl2 + ouabain 112.3 ± 12.1

*
*

Exercise minute 5
Control
BaCl2

168.0 ± 15.5
119.0 ± 16.8

BaCl2 + ouabain 111.2 ± 11.8

*
*

Values are means ± SE; n = 8 subjects.
*

P < 0.05 vs. control. †P < 0.05 vs. BaCl2 + ouabain.
MAP: main effect of condition (BaCl2 + ouabain vs. both control and BaCl2; P < 0.05); main effect of time
point (minute 5 vs. rest and minute 1; P < 0.05); no significant interaction [(P = 0.23); 0.05]; main effect of
time point (minutes 1–5 vs. rest; P < 0.05); no significant interaction (P = 0.39).
‡

Fig. 2.

Protocol 1: effect of inhibition of hyperpolarizing and endotheliumdependent vasodilator mechanisms on the onset of
exercise hyperemia. A: forearm blood flow (FBF) across the 3 experimental conditions is shown at rest and during 10%
MVC rhythmic handgrip exercise. Data are in 3s bins corresponding to a contraction:relaxation cycle during exercise. B:
statistical analysis was performed on 15s averages of blood flow data (5 3s bins). BaCl2 + ouabain significantly reduced
the onset of exercise hyperemia, and LNMMA + ketorolac had an additional effect within the first 15 s of exercise. *P <
0.05 vs. control; †P < 0.05 vs. BaCl2 + ouabain; n = 11 subjects.
Fig. 3.

Protocol 2: effect of inhibition of hyperpolarizing and endotheliumdependent vasodilator mechanisms on steadystate

exercise hyperemia. In protocol 2, with continuous infusion of the inhibitors, a significant reduction in FBF (A) and forearm
vascular conductance (FVC; B) was observed with combined BaCl2 + ouabain infusion. Here, the addition of LNMMA +
ketorolac to BaCl2 + ouabain further reduced both steadystate FBF and FVC. RHG Ex, rhythmic handgrip exercise. *P <
0.05 vs. control; †P < 0.05 vs. BaCl2 + ouabain; n = 8 subjects.
Fig. 4.

Protocol 3: effect of independent inhibition of KIR channels on exercise hyperemia. A: FBF across the 3 experimental

conditions is shown at rest and during 10% MVC rhythmic handgrip exercise. Data are in 3s bins corresponding to a
contraction:relaxation cycle during exercise. B: statistical analysis was performed on 15s averages of blood flow data (5 3s
bins). In all inhibited conditions, exercise hyperemia was lower from 30 to 300 s. *P < 0.05 vs. BaCl2; vs. BaCl2 + ouabain.
After 15 s, there was no statistically significant reduction with infusion of BaCl2 + ouabain. †P < 0.05 vs. BaCl2; n = 8
subjects.
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